ASHLAND INC.
Moat Score — Ashland Inc.
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Ashland holds a large portfolio of specialty ingredient formulations, applications know-how, and regulatory filings (particularly in pharmaceutical excipients) developed over decades, representing real, if not maximally unique, intellectual capital. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Ashland's scale in specific specialty ingredient categories provides moderate manufacturing efficiency, but it competes against larger diversified chemical giants like BASF and Dow that have greater overall scale. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | In its Life Sciences segment particularly, embedded ingredient positions within regulated drug formulations support strong pricing power, while Personal Care and Specialty Additives face more competitive, formulation-dependent pricing dynamics. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in specialty chemical ingredient supply. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Once a pharmaceutical excipient or personal care ingredient is qualified into a customer's approved formulation or regulatory filing, switching suppliers requires costly and time-consuming re-validation, re-testing, and potential regulatory refiling, creating substantial switching costs, particularly in Life Sciences. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Global manufacturing and regulatory quality compliance infrastructure required for pharmaceutical-grade ingredients represents a real barrier to entry, though Ashland still competes against several other well-capitalized specialty ingredient suppliers in each of its end markets. |